JCB, Volume 16, Number 2, 2010 Editorial Vol.16 No. 2 (2010) Case studies in innovation: What enables outstanding achievements? Yali Friedman In fostering innovation, be it in biotechnology or in another field, a persistent challenge is to understand the factors enabling success. It is not sufficient to simply be Article Vol.16 No. 2 (2010) Biotechnology marketing: Insider and outsider views Päivi Eriksson This paper explores biotechnology marketing as defined, performed and organised in small biotechnology companies. Prior research has argued on the one hand that marketi Article Vol.16 No. 2 (2010) The current M&A environment and its strategic implications for emerging biotherapeutics companies Mohan Sowlay The age of the blockbuster drug may have come and gone. With dwindling pipelines and increasing generic competition, pharmaceutical companies continue to create efficie Article Vol.16 No. 2 (2010) Practical approaches to early stage life sciences technology valuations Stephen Mayhew With fierce competition in the market for late stage life sciences assets, pharmaceutical companies seeking partnering strategies to bolster pipelines and drive long-te Article Vol.16 No. 2 (2010) Commercializing synthetic biology: Socio-ethical concerns and challenges under intellectual property regime Trichi Saukshmya Synthetic biology also termed as ‘genomic alchemy’ represents a powerful area of science that is based on the convergence of biological sciences with syste Article Vol.16 No. 2 (2010) From carbon to carbohydrates: Corporate strategies for biopolymer technology development Avrath Chadha Since a few years the worldwide demand for biopolymers is increasing significantly. Many firms are trying to avoid the price spiral of fossil fuels by utilising renewab Article Vol.16 No. 2 (2010) Biotechnology in the capital region of Europe Jan Wauters It has never been as challenging in biotechnology as today. Convergence is the key word, forcing alliances between pharmaceuticals and biology, and new economic opportu Legal and Regulatory Updates Vol.16 No. 2 (2010) Legal and regulatory update Gerry Kamstra   Conference Report Vol.16 No. 2 (2010) Funding the dream at the Mid-Atlantic Biotech Conference Harley King   Book Review Vol.16 No. 2 (2010) Book Review: Getting to Plan B: Breaking through to a better business model Arlen D Meyers Getting to Plan B: Breaking through to a better business modelJohn Mullins and Randy KomisarHarvard Business School Press, Boston, MA, 2009, hardback, 249pp.,ISBN: 97 Book Review Vol.16 No. 2 (2010) Book Review: Driving innovation – Intellectual property strategies for a dynamic world Barry J Marenberg Driving innovation – Intellectual property strategies for a dynamic worldMichael A. GollinCambridge University Press, New York, 2008, paperback, 415pp.,ISBN: 9 Book Review Vol.16 No. 2 (2010) Book Review: Intellectual property, medicine and health: Current debates Stanley P Kowalski Intellectual property, medicine and health: Current debatesJohanna GibsonAshgate, Farnham, England and Burlington, VT, USA, 2009, hardback, 223pp.,ISBN: 978-075467218
